… ProQR Announces Proposed Underwritten Public Offering of … and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters …
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
AX-0810 targeting NTCP for cholestatic diseases to be first ProQR Axiomer™ RNA editing program to enter the clinic Company to host virtual Investor and Analyst Event in December to highlight translational data and clinical plans for AX-0810, as well as AX-1412, targeting
… ProQR Announces First Quarter 2021 Operating and Financial … & CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … for the same period last year. Research and development (R&D) costs were €8.9 million for the quarter ended March 31, …
… ProQR to Present at Two Investor Conferences in September … at 9:10am ET, Daniel de Boer, Chief Executive Officer of ProQR, will present at the Cantor Fitzgerald Global … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w